Drug Discovery & Pharmaceuticals

RSS

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer.

From Avacta Life Sciences Ltd. 28 Jan 2020

Determining Microsatellite Instability Status Using Multiplex PCR-Based Methods

Determining microsatellite instability status using multiplex PCR-based methods used to screen for Lynch Syndrome, a dominant hereditary cancer propensity.

From Promega Corporation 24 Jan 2020

Sensitive Analysis of Sugars with HPLC-Electrochemical Detection

An interview with Dr. Kristin Folmert, Application & Academy, KNAUER Wissenschaftliche Geräte GmbH.

From KNAUER Wissenschaftliche Geräte GmbH 23 Jan 2020

New approach for the manufacture of Advanced Therapy Medicinal Products

Akron Biotechnology has proposed a new approach for the qualification of ancillary materials for the manufacture of Advanced Therapy Medicinal Products.

22 Jan 2020

New software that provides increased visualization tools for labs

Biosero, Inc. will release new software products and features, at the 2020 Society for Laboratory Automation and Screening Conference (SLAS 2020).

From Biosero Inc. 22 Jan 2020

High-speed, precise liquid and gas handling products at SLAS 2020

Festo debuts a new generation of high speed, flexible, and precise liquid dispensing and gas handling products at SLAS, January 27-29, in San Diego.

22 Jan 2020

Powerful combination of experimental drugs reverses osteoarthritis in rats

People with osteoarthritis, or "wear and tear" arthritis, have limited treatment options: pain relievers or joint replacement surgery.

21 Jan 2020

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Turbine, a simulation-first drug discovery company, today announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.

21 Jan 2020

Enterprise Therapeutics publishes open access paper on novel approach to treat cystic fibrosis

Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of its first peer-reviewed paper.

21 Jan 2020

SITESEEKER to be used for Otsuka’s therapeutics discovery programs

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, in disease-relevant pathways nominated by Otsuka.

From PhoreMost 21 Jan 2020

Editor's Pick: Life Science Interviews from 2019

In this article, our editors look back at their favorite life science interviews from 2019.

17 Jan 2020

Molecular-level understanding of drug interactions could pave way for better malaria treatments

The process of crystallization is central to drug development, petrochemical processing and other industrial actions, but scientists say they still are learning about the complex interactions involved in the building and dissolution of crystals.

16 Jan 2020

How SpatialOMx is Delivering New Insights into Disease Research

An interview with Shannon Cornett Ph.D, discussing the use of MALDI-guided spatial molecular analysis for biomarker discovery.

From Bruker Life Sciences Mass Spectrometry 14 Jan 2020

Scientists secure funding to develop better methods for evaluation of topically applied drugs

A team of leading scientists from Bath University UK, the UK's National Physical Laboratory, and the Colorado School of Mines USA has secured funding from the US Food and Drug Administration to develop better methods to assess the performance of topically applied drug products.

10 Jan 2020

Avacta and Daewoong Pharmaceutical announce joint venture to develop novel cell and gene therapies

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, are pleased to announce that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

From Avacta Life Sciences Ltd. 9 Jan 2020

Novel study on molecular interactions could make it easier to develop new medicines

A first-of-its-kind study on molecular interactions by biomedical engineers in the University of Minnesota's College of Science and Engineering will make it easier and more efficient for scientists to develop new medicines and other therapies for diseases such as cancer, HIV, and autoimmune diseases.

3 Jan 2020

Drug Discovery & Pharmaceuticals

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Determining Microsatellite Instability Status Using Multiplex PCR-Based Methods

Sensitive Analysis of Sugars with HPLC-Electrochemical Detection

New approach for the manufacture of Advanced Therapy Medicinal Products

New software that provides increased visualization tools for labs

High-speed, precise liquid and gas handling products at SLAS 2020

Powerful combination of experimental drugs reverses osteoarthritis in rats

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Enterprise Therapeutics publishes open access paper on novel approach to treat cystic fibrosis

SITESEEKER to be used for Otsuka’s therapeutics discovery programs

Editor's Pick: Life Science Interviews from 2019

Molecular-level understanding of drug interactions could pave way for better malaria treatments

How SpatialOMx is Delivering New Insights into Disease Research

Scientists secure funding to develop better methods for evaluation of topically applied drugs

Avacta and Daewoong Pharmaceutical announce joint venture to develop novel cell and gene therapies

Novel study on molecular interactions could make it easier to develop new medicines

Studying Alzheimer’s and Parkinson’s Disease using Pre-Formed Fibrils

Scientists identify molecules capable of inhibiting DNA methylation, effectively killing malaria parasites

NIH awards $1.2 million grant for studying biomolecular interactions to inform better drug design

Developing less aggressive cancer drugs that enable the immune system to recognize tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News